Quick answers
- What is Scopolamine used for?
- The FDA-approved label (Transderm Scop, Baxter Healthcare Corporation, June 10, 2025) says: “TRANSDERM SCŌP is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. TRANSDERM SCŌP is an anticholinergic indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Scopolamine have a boxed warning?
- No. None of the 21 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Scopolamine?
- The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated November 3, 2025). Ask your pharmacist about alternatives.
- Has Scopolamine been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started April 13, 2022 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Scopolamine?
- 12 companies list prescription products of Scopolamine in the FDA NDC Directory, including Bryant Ranch Prepack, A-S Medication Solutions and Zydus Pharmaceuticals USA Inc..
What Scopolamine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
TRANSDERM SCŌP is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. TRANSDERM SCŌP is an anticholinergic indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. …
— FDA label: Transderm Scop, Baxter Healthcare Corporation, effective June 10, 2025. Read the full label on DailyMed →
The FDA has 21 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 21 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Patch, extended release · Patch · System |
|---|---|
| Route | Transdermal |
| Prescription products | 22 in the FDA NDC Directory |
| Brand names | Scopolamine Trandermal System, Transderm Scop |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| scopolamine 1 mg patch, extended release | Generic | $4.22 per patch |
| scopolamine 1 mg/3 d patch | Generic | $4.22 per patch |
| scopolamine 1 mg/3 d patch, extended release | Generic | $4.22 per patch |
| scopolamine 1 mg/3 d patch, extended release | Brand: Transderm Scop | $10.57 per patch |
| scopolamine 1 mg/3 d system | Generic | $4.22 per unit |
| scopolamine 1.5 mg patch, extended release | Generic | $4.22 per patch |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack9 products
- A-S Medication Solutions3 products
- Zydus Pharmaceuticals USA Inc.1 product
- Zydus Lifesciences Limited1 product
- Amneal Pharmaceuticals NY LLC1 product
- Mylan Pharmaceuticals Inc.1 product
- Rhodes Pharmaceuticals LLC1 product
- NuCare Pharmaceuticals, Inc.1 product
- Actavis Pharma, Inc.1 product
- Padagis Israel Pharmaceuticals Ltd1 product
- Ingenus Pharmaceuticals, LLC1 product
- Baxter Healthcare Corporation1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA017874 TRANSDERM SCOP | Baxter Hlthcare Corp | December 31, 1979 | 30, latest June 10, 2025 2025: Manufacturing (CMC) · 2025: Labeling · 2024: Labeling |
Generic approvals (7)
- ANDA078830Difgen Pharms · January 30, 2015
- ANDA203753Mylan Technologies · June 19, 2019
- ANDA212342Riconpharma LLC · November 24, 2020
- ANDA208769Actavis Labs Ut Inc · January 10, 2022
- ANDA215329Rhodes Pharms · May 6, 2024
- ANDA217893Zydus Pharms · August 29, 2024
- ANDA218384Amneal · June 9, 2025
Shortage status
To be discontinued · updated November 3, 2025 · first posted November 3, 2025
| Product | Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46) |
|---|---|
| Company | Padagis US LLC |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
April 13, 2022 · Class II · Terminated · D-1083-2022
cGMP deviations: Temperature abuse
Transderm Scop (scopolamine) Transdermanl System, 1 mg/ 3 days, 10 (patches) transdermal Systems Multipack, Rx only, MFG: Baxter Healthcare Corp, NDC 10019-553-03 — Mckesson Medical-Surgical Inc. Corporate Office
-
May 11, 2018 · Class II · Terminated · D-0816-2018
Defective delivery system
Scopolamine Transdermal Therapeutic System, 1 mg/3 days, a) 4-count (NDC 45802-580-84); b) 10-count (NDC 45802-580-46); c) 24-count (NDC 45802-580-62), Rx only, Mfd. by: Aveva Drug Delivery Systems, A Nitto Denko Company — L. Perrigo Company
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 226552, 351875 |
|---|---|
| SPL set ID of the quoted label | b877a694-a1d0-4280-937a-a06820b12a88 |
| FDA labels (SPL) | 21 |
| FDA applications | NDA017874, 7 ANDA |
| Active ingredients (FDA) | SCOPOLAMINE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Transderm Scop, Baxter Healthcare Corporation, effective June 10, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →